Review: 2016 Oncology Nursing Drug Handbook “should be in every oncology floor’s medication room”

2016 Oncology Nursing Drug HandbookThe good reviews have already started for 2016 Oncology Nursing Drug Handbook by Gail M. Wilkes and Margaret Barton-Burke. According to Melissa Mason, BSN, RN, CPN, CPHON, from the University of New Mexico Hospital, writing for Doody’s Review Service,

“This is an essential part of any oncology nurse’s library and should be in every oncology floor’s medication room.”

Written especially for nurses caring for patients with cancer, the 2016 Oncology Nursing Drug Handbook uniquely expresses drug therapy in terms of the nursing process: nursing diagnoses, etiologies of toxicities, and key points for nursing assessment, intervention, and evaluation.

  • Offers valuable information on effective symptom management, patient education, and chemotherapy administration
  • Includes a simplified chapter on molecular and biological targeted therapy that incorporates new information about immunotherapy
  • Provides new indications and the most important and common side effects

New drugs include: blinatumomab (Blincyto), ceftazidime/avibactam (Avycaz), ceftolozane/tazobactam (Zerbaxa), dalbavancin (Dalvance), dinutuximab (Unituxin), filgrastim-sndz (Zarxio), isavuconazonium sulfate (Cresemba), lanreotide (Somatuline Depot Injection), lenvatinib (Lenvima), naloxegol (Movantik), Netupitant/palonosetron (Akynzeo), nivolumab (Opdivo), olaparib (Lynparza), oritavancin (Orbactiv), palbociclib (Ibrance), panobinostat (Farydak), sonidegib (Odomzo), and tedizolid phosphate (Sivextro).

Can’t wait to learn more? Visit our website.

This entry was posted in Nursing, Oncology, Pharmacology and tagged , , , , , , , . Bookmark the permalink.

Comments are closed.